Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A conformational variant of p53 (U-p53AZ) as blood-based biomarker for the prediction of the onset of symptomatic Alzheimer’s disease

View ORCID ProfileSimona Piccirella, Leander Van Neste, View ORCID ProfileChristopher Fowler, Colin L Masters, Jurgen Fripp, James D. Doecke, Chengjie Xiong, View ORCID ProfileDaniela Uberti, Paul Kinnon
doi: https://doi.org/10.1101/2021.08.23.21261848
Simona Piccirella
aDiadem srl, Brescia, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Simona Piccirella
  • For correspondence: s.piccirella@diademdx.com
Leander Van Neste
bHalixo BV, Hoegaarden, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Fowler
cThe Florey Institute of Neuroscience and Mental Health, Parkville, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christopher Fowler
Colin L Masters
cThe Florey Institute of Neuroscience and Mental Health, Parkville, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jurgen Fripp
dThe Australian e-Health Research Centre, CSIRO, Herston, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James D. Doecke
dThe Australian e-Health Research Centre, CSIRO, Herston, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chengjie Xiong
eWashington University School of Medicine, Division of Biostatistics, Saint Louis, MO, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Uberti
fDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
gMolecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daniela Uberti
Paul Kinnon
aDiadem srl, Brescia, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Ongoing research seeks to identify blood-based biomarkers able to predict the onset and progression of Alzheimer’s disease (AD). A potential biomarker is the unfolded conformational variant of p53, previously observed in individuals in the prodromal and clinical AD stages. In this retrospective study, we compare diagnostic and prognostic performances of measures of the amyloid β load with those of a conformational variant of U-p53 in plasma samples from individuals participating in the Australian Imaging, Biomarkers and Lifestyle (AIBL) cohort.

Methods Immunoprecipitation (IP) followed by liquid chromatography (LC) tandem mass spectrometry (MS/MS) and protein sequencing in plasma samples from the AIBL study identified the clinically relevant AZ 284® peptide, representing a measure of the U-p53 conformational variant (U-p53AZ). Based on U-p53AZ quantification via IP/LC electrospray ionisation-coupled MS/MS (AlzoSure® Predict test) on 515 samples from 482 individuals from the AIBL cohort, the predictive performance of U-p53AZ was assessed and compared with amyloid load as measured by amyloid β-positron emission tomography (Aβ-PET). Its predictive performance was determined at 36, 54, 72 and 90 months following baseline assessment.

Results U-p53AZ was able to identify individuals with AD dementia with an area under the receiver operating characteristic curve (AUC) of 99%. U-p53AZ outperformed the conventional Aβ-PET measures in predicting the onset of AD dementia both from preclinical (AUC=98%) and prodromal stages (AUC=89%), even 90 months prior to onset (AUC=99%). Additionally, the estimated predictive performance of U-p53AZ was superior (AUC ≥98%) to other risk factors (i.e., gender, Aβ-PET and APOE ε4 allele status) in identifying individuals at high risk for progression to AD.

Conclusion These findings support use of U-p53AZ as blood-based biomarker predicting if individuals, at both asymptomatic and MCI stages, would progress to AD at least six years prior to the onset of clinical AD dementia.

  • Alzheimer’s disease
  • blood-based biomarker
  • AD
  • p53
  • prognosis
  • U-p53

Competing Interest Statement

The ownership of the 2D3A8 antibody patent rights belongs to Diadem srl, Brescia, Italy. The registered trademark AlzoSure Predict was developed by Diadem srl, Brescia, Italy. SP and PK are employees of Diadem srl, Brescia, Italy. DU is co-founder and CSO of Diadem srl, Spin Off of Brescia University, Brescia, Italy. LVN and CX are consultants of Diadem srl.

Funding Statement

This study was funded by Diadem srl, Brescia, Italy.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Human Research Ethics Committee, Research Governance Unit, St Vincent's Healthcare, Australia (no. 028/06)

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data available on request from the authors.

  • Abbreviations

    Aβ
    Amyloid beta
    AIBL
    Australian Imaging, Biomarkers, and Lifestyle
    AUC
    Area under the receiver operating characteristic curve
    AD
    Alzheimer’s disease
    APOE ε4
    Apolipoprotein E ε4 allele
    BACE1
    β-site amyloid precursor protein-cleaving enzyme 1
    CI
    Confidence interval
    CN
    Cognitively normal
    CSF
    Cerebrospinal fluid
    ELISA
    Enzyme linked immunosorbent assay
    ESI
    Electrospray ionisation
    HCD
    Higher energy collision-induced dissociation
    HPLC
    High performance liquid chromatography
    IP
    Immunoprecipitation
    MCI
    Mild cognitive impairment
    MRI
    Magnetic resonance imaging
    MS/MS
    Tandem mass spectrometry
    OD
    Other types of dementias
    PiB-PET
    Positron emission tomography utilising Pittsburgh compound B
    ROC
    Receiver operating characteristic
    PTMs
    Post-translational modifications
    RNS/ROS
    Reactive nitrogen/reactive oxygen species
    SACI
    Surface-activated chemical ionisation
    U-p53
    unfolded p53
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted August 25, 2021.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    A conformational variant of p53 (U-p53AZ) as blood-based biomarker for the prediction of the onset of symptomatic Alzheimer’s disease
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    A conformational variant of p53 (U-p53AZ) as blood-based biomarker for the prediction of the onset of symptomatic Alzheimer’s disease
    Simona Piccirella, Leander Van Neste, Christopher Fowler, Colin L Masters, Jurgen Fripp, James D. Doecke, Chengjie Xiong, Daniela Uberti, Paul Kinnon
    medRxiv 2021.08.23.21261848; doi: https://doi.org/10.1101/2021.08.23.21261848
    Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
    Citation Tools
    A conformational variant of p53 (U-p53AZ) as blood-based biomarker for the prediction of the onset of symptomatic Alzheimer’s disease
    Simona Piccirella, Leander Van Neste, Christopher Fowler, Colin L Masters, Jurgen Fripp, James D. Doecke, Chengjie Xiong, Daniela Uberti, Paul Kinnon
    medRxiv 2021.08.23.21261848; doi: https://doi.org/10.1101/2021.08.23.21261848

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Neurology
    Subject Areas
    All Articles
    • Addiction Medicine (161)
    • Allergy and Immunology (416)
    • Anesthesia (91)
    • Cardiovascular Medicine (859)
    • Dentistry and Oral Medicine (159)
    • Dermatology (97)
    • Emergency Medicine (250)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (394)
    • Epidemiology (8562)
    • Forensic Medicine (4)
    • Gastroenterology (384)
    • Genetic and Genomic Medicine (1752)
    • Geriatric Medicine (167)
    • Health Economics (373)
    • Health Informatics (1244)
    • Health Policy (621)
    • Health Systems and Quality Improvement (468)
    • Hematology (196)
    • HIV/AIDS (374)
    • Infectious Diseases (except HIV/AIDS) (10303)
    • Intensive Care and Critical Care Medicine (553)
    • Medical Education (192)
    • Medical Ethics (51)
    • Nephrology (212)
    • Neurology (1678)
    • Nursing (97)
    • Nutrition (251)
    • Obstetrics and Gynecology (326)
    • Occupational and Environmental Health (451)
    • Oncology (929)
    • Ophthalmology (263)
    • Orthopedics (102)
    • Otolaryngology (172)
    • Pain Medicine (114)
    • Palliative Medicine (40)
    • Pathology (253)
    • Pediatrics (535)
    • Pharmacology and Therapeutics (253)
    • Primary Care Research (208)
    • Psychiatry and Clinical Psychology (1770)
    • Public and Global Health (3841)
    • Radiology and Imaging (624)
    • Rehabilitation Medicine and Physical Therapy (320)
    • Respiratory Medicine (520)
    • Rheumatology (208)
    • Sexual and Reproductive Health (168)
    • Sports Medicine (158)
    • Surgery (190)
    • Toxicology (36)
    • Transplantation (101)
    • Urology (76)